This finding may explain the therapeutic efficacy of Cepharanthin® for the management of pediatric chronic ITPs, as CD4+ T cell proliferative responses were observed in cultures of PBMCs obtained from ITP patients in contrast to healthy donors [8, 21]. The gene discussed is CD4; the disease is autoimmune thrombocytopenic purpura.